UCSF, Pfizer, and Stanford investigators developed a novel anti-IL2 mAb for the treatment of autoimmune and inflammatory diseases, including without limitation, Type I diabetes mellitus, psoriasis, Crohn's disease, adult respiratory distress syndrome, rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, and autoimmune thyroiditis. Unlike other treatments for autoimmune and inflammatory diseases, this antibody targets the underlying pathogenic pathway rather than merely treating the symptoms. Specifically, when complexed with IL-2, this antibody can selectively expand regulatory T-cells (Tregs) by releasing IL-2 specifically to Tregs.
Existing low dose IL-2 and IL-2 Mutein therapies show clinical promise, but have a narrow therapeutic window. Too high doses can cause cancer, while insufficient doses are ineffective. The specificity of the therapeutic described here would allow for higher doses without carcinogenic side effects. Furthermore, this antibody complex is less complicated to manufacture than Pegylated IL2.
|United States Of America||Issued Patent||10,138,298||11/27/2018||2014-100|
|European Patent Office||Published Application||3365369||08/29/2018||2014-100|
|Rep Of Korea||Published Application||10-2018-0064541||06/14/2018||2014-100|
|New Zealand||Published Application||2014-100|
Additional Patents Pending